Interestingly, CD33-CAR-T cells from AML patients showed a statistically significant reduction of the antitumor activity with reduced survival compared to CAR-T cells from healthy donors (adult and senior) (Figure 3F). The gene discussed is CD33; the disease is acute myeloid leukemia.